FLT3 inhibition combines with ATRA to cause regression of leukemia.

Sublethally irradiated mice that were recipients of activated FLT3/PML-RARα leukemic cells were treated with 10 mg ATRA or placebo pellets. After 4 days of treatment, mice were analyzed. Percentages of leukocytes that expressed GFP in blood, bone marrow, and spleen are shown. ■ indicates placebo; ▨, SU11657; ░, ATRA; and ▪, ATRA + SU11657. Error bars represent standard deviation.